Filed by Ohio Attorney General Mike DeWine, the lawsuit alleges, among other things, that the false marketing included medical journal advertising, sales representative statements, and the use of front groups to deliver information which downplayed the risks and inflated the benefits of certain formulations of opioids. This behavior proliferated the prescription of opioids and fueled the opioid epidemic Ohio is currently facing.
The suit names Purdue Pharma, marketer of OxyContin, MS Contin, Dilaudid, Butrans, Hyslingla, and Targiniq; Endo Health Solutions, the marketer of Percocet, Percodan, Opana and Zydone; Teva Pharmaceutical Industries and its subsidiary Cephalon, the marketers Actiq and Fentora; Johnson & Johnson and its subsidiary Janssen Pharmaceuticals, marketers of Duragesic and Nucynta; and Allergan, marketer of Kadian, Norco and a multitude of generic opioids.
READ MORE opioid addiction and dangerous drugs LEGAL NEWS
- The Right To Walk: Why Everyone Should Have Access to Sidewalks and Crosswalks
- Attorney is Hopeful Current Opioid Litigation will Pave the Way for Individual Opioid Lawsuits
- Social Worker and Mother in Recovery 30 years from Opioid Prescriptions, Son Died from Overdose
"We believe the evidence will also show that these companies got thousands and thousands of Ohioans our friends, our family members, our co-workers, our kids, addicted to opioid pain medications, which has all too often led to use of the cheaper alternatives of heroin and synthetic opioids," DeWine said in a statement.
DeWine contends that the drug manufacturers led prescribers to believe that opioids were not addictive, that addiction was an easy thing to overcome, or that addiction could actually be treated by taking even more opioids.
“They knew they were wrong, but they did it anyway, and they continue to do it,” DeWine said.